Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

Yoshimura, Reiji; Ueda, Nobuhisa; Hori, Hikaru; Ikenouchi-Sugita, Atsuko; Umene-Nakano, Wakako; Nakamura, Jun

doi:10.1080/15622970802309617

Cited by 9 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypofunction of noradrenergic neurons have been associated with the impaired working memory. Actually, we reported that plasma MHPG levels in patients with first-episode schizophrenia were significantly lower than those in healthy controls, and treatment with atypical antipsychotic drugs such as risperidone, olanzapine, and aripiprazole significantly increased plasma MHPG levels, which was associated with the improvement of negative symptoms of schizophrenia (Yoshimura et al, 2000a(Yoshimura et al, , 2008Hori et al, 2007). We demonstrated in a previous study that atypical antipsychotic drugs inhibited noradrenaline transporters (Yoshimura et al, 2000b(Yoshimura et al, , 2001(Yoshimura et al, , 2005.…”

Section: Discussionmentioning

confidence: 83%

Associations between plasma levels of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early‐stage schizophrenia

Gotō

Yoshimura

Kakeda

et al. 2009

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

Schizophrenic patients demonstrate a variety of cognitive deficits, including attention, executive functions, and working memory, even in the early stage of disease. In the present study, we examined the association between blood levels of 3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), or brain-derived neurotrophic factor (BDNF) and scores on the Wisconsin Card Sorting Test (WCST) in patients with early-stage schizophrenia. We also investigated the association between frontal GABA levels using 1H-magnetic resonance spectroscopy (MRS) at 3T and scores on the WCST in the same patients. Blood levels of BDNF and catecholamine metabolites and brain GABA levels using 1H-MRS were measured in 18 schizophrenic patients (nine males, nine females; age range 13-52 year). A significantly positive correlation was observed between plasma MHPG levels and %PEM (rho = -0.686, p = 0.0047). A trend toward negative correlation was found between frontal lobe GABA levels and the per cent of preservation error (%PEM) in the early stage of schizophrenia (rho = -0.420, p = 0.0836). These results suggest that noradrenergic neurons might be involved in neuropsychological functions in early-stage of schizophrenia.

show abstract

Section: Discussionmentioning

confidence: 83%

Associations between plasma levels of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early‐stage schizophrenia

Gotō

Yoshimura

Kakeda

et al. 2009

Human Psychopharmacology

Self Cite

View full text Add to dashboard Cite

show abstract

“…This suggests that the turnover of monoamines in both the occurrence and the improvement of relapses due to DSP may be lower compared to their turnover in FEP. Many research groups have reported that the blood concentrations of HVA or MHPG were decreased during the psychopathological improvement among patients under an acute state (Bowers et al, 1989;Davidson et al, 1991;Davila et al, 1988;Koreen et al, 1994;Miura et al, 2012Nagaoka et al, 1997Pickar et al, 1984;Yoshimura et al, 2010), but these results were not completely consistent in all studies of a similar kind (Zumárraga et al, 2011;Nikisch et al, 2010). Several PET studies demonstrated higher dopamine synthesis within presynaptic dopaminergic neurons in FEP patients and drug-free patients relative to that in a normal control group (Howes et al, 2012), which may partly explain the finding of elevated dopamine turnover at the very early phase as observed in the studies measuring the concentrations of monoamine in patients under FEP (Bowers et al, 1989;Davila et al, 1988;Nagaoka et al, 1997;Pickar et al, 1984).…”

Section: Discussionmentioning

confidence: 99%

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis

et al. 2020

View full text Add to dashboard Cite

Background: Patients with first-episode psychosis respond well to initial antipsychotic treatment, but among patients experiencing a relapse of psychosis, the response rate falls to approximately 30%. The mechanism of this discrepancy has not been clarified, but the development of dopamine supersensitivity psychosis with the underlying up-regulation of post-synaptic dopamine D2 receptors could be involved in this lesser response. It is uncertain whether elevated dopamine synthesis and release occurs in patients with dopamine supersensitivity psychosis, in contrast to those with first-episode psychosis. Patients and methods: We examined a first-episode psychosis group ( n=6) and a chronic schizophrenia group, i.e. patients experiencing relapse ( n=23) including those who relapsed due to dopamine supersensitivity psychosis ( n=18). Following the initiation of treatment, we measured the patients’ blood concentrations of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol at two weeks and four weeks after the baseline measurements. Results: The first-episode psychosis group tended to show decreased homovanillic acid, accompanied by an improvement of symptoms. The chronic schizophrenia group showed no alteration of homovanillic acid or 3-methoxy-4-hydroxyphenylglycol over the treatment period. These results were the same in the dopamine supersensitivity psychosis patients alone. Conclusions: Our findings suggest that unlike first-episode psychosis, the release of dopamine from presynaptic neurons did not increase in relapse episodes in the patients with dopamine supersensitivity psychosis. This indirectly indicates that the development of supersensitivity of post-synapse dopamine D2 receptor is involved in relapse in dopamine supersensitivity psychosis patients.

show abstract

“…No significant increases in body weight, blood glucose level, total cholesterol level, LDL cholesterol level, and triglycerides were seen relative to before the start of treatment. Furthermore, a short‐term (eight weeks) cohort study which compared aripiprazole, olanzapine, and risperidone in Japanese populations 7 showed that improvements in the positive syndrome, negative syndrome, and overall psychopathology scores of the Positive and Negative Syndrome Scale (PANSS) were as follows: aripiprazole—23%, 26%, 26%; olanzapine—30%, 28%, 28%; and risperidone—32%, 25%, and 29%. Two RCTs 8,9 which compared olanzapine and risperidone showed that there were no differences in efficacy between the two but that olanzapine increased body weight and risperidone tended to cause more EPS.…”

Section: Cq1‐1 Which Antipsychotics Are Recommended For the Treatment Of First‐episode Psychosis?mentioning

confidence: 99%

Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”

2021

Neuropsychopharm Rep

View full text Add to dashboard Cite

Different patterns of longitudinal changes in plasma levels of catecholamine metabolites and brain-derived neurotrophic factor after administration of atypical antipsychotics in first episode untreated schizophrenic patients

Cited by 9 publications

References 0 publications

Associations between plasma levels of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early‐stage schizophrenia

Associations between plasma levels of 3‐methoxy‐4‐hydroxyphenylglycol (MHPG) and negative symptoms or cognitive impairments in early‐stage schizophrenia

Plasma monoamines change under dopamine supersensitivity psychosis in patients with schizophrenia: A comparison with first-episode psychosis

Japanese Society of Neuropsychopharmacology: “Guideline for Pharmacological Therapy of Schizophrenia”

Contact Info

Product

Resources

About